Haggarty C, Molla H, Glazer J, Tare I, Rains A, de Wit H
Psychedelic Med (New Rochelle). 2025; 2(4):210-220.
PMID: 40051483
PMC: 11658383.
DOI: 10.1089/psymed.2024.0005.
Petruskova A, Guhathakurta D, Akdas E, Perello-Amoros B, Frischknecht R, Weiss E
J Neurochem. 2025; 169(3):e70020.
PMID: 40022486
PMC: 11871419.
DOI: 10.1111/jnc.70020.
Weiss F, Magnesa A, Gambini M, Gurrieri R, Annuzzi E, Elefante C
Brain Sci. 2025; 15(2).
PMID: 40002450
PMC: 11853016.
DOI: 10.3390/brainsci15020117.
Kurzbaum E, Palenicek T, Shrchaton A, Azerrad S, Dekel Y
J Fungi (Basel). 2025; 11(2).
PMID: 39997393
PMC: 11856550.
DOI: 10.3390/jof11020099.
Iyer R, Favela D, Domokos A, Zhang G, Avanes A, Carter S
Nat Chem. 2025; 17(3):412-420.
PMID: 39915657
DOI: 10.1038/s41557-024-01714-7.
Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.
Kinderlehrer D
Neuropsychiatr Dis Treat. 2025; 21:141-155.
PMID: 39897712
PMC: 11787777.
DOI: 10.2147/NDT.S500337.
Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'.
OConnor S, Godfrey K, Reed S, Peill J, Rohani-Shukla C, Healy M
Cureus. 2025; 17(1):e78171.
PMID: 39882198
PMC: 11775745.
DOI: 10.7759/cureus.78171.
Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis.
van der Heijden K, Otto M, Schoones J, van Esdonk M, Borghans L, van Hasselt J
Clin Pharmacokinet. 2025; 64(2):215-227.
PMID: 39838235
PMC: 11782443.
DOI: 10.1007/s40262-024-01450-8.
Exploring the Therapeutic Potential of Psychedelics in Chronic Pain Management: A New Frontier in Medicine.
Lin C, Wang X, Wang X
Neurosci Bull. 2025; .
PMID: 39832122
DOI: 10.1007/s12264-025-01351-1.
Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis.
Otto M, van der Heijden K, Schoones J, van Esdonk M, Borghans L, Jacobs G
Clin Pharmacokinet. 2025; 64(1):53-66.
PMID: 39812743
PMC: 11762572.
DOI: 10.1007/s40262-024-01454-4.
The Influence of Phosphoinositide Lipids in the Molecular Biology of Membrane Proteins: Recent Insights from Simulations.
Hedger G, Yen H
J Mol Biol. 2025; 437(4):168937.
PMID: 39793883
PMC: 7617384.
DOI: 10.1016/j.jmb.2025.168937.
Pharmacokinetics and pharmacodynamics of an innovative psychedelic N,N-dimethyltryptamine/harmine formulation in healthy participants: a randomized controlled trial.
Mueller M, Aicher H, Dornbierer D, Marten L, Suay D, Meling D
Int J Neuropsychopharmacol. 2025; 28(1).
PMID: 39774840
PMC: 11770821.
DOI: 10.1093/ijnp/pyaf001.
Psilocybin: From Psychiatric Pariah to Perceived Panacea.
Fonzo G, Wolfgang A, Barksdale B, Krystal J, Carpenter L, Kraguljac N
Am J Psychiatry. 2025; 182(1):54-78.
PMID: 39741437
PMC: 11694823.
DOI: 10.1176/appi.ajp.20230682.
Toward Translatable Biomarkers of Psychedelic-Induced Neuroplasticity.
Olson D
Am J Psychiatry. 2025; 182(1):10-12.
PMID: 39741436
PMC: 11822763.
DOI: 10.1176/appi.ajp.20231054.
The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature.
Pulido-Saavedra A, Borelli A, Kitaneh R, Alrafayia M, Jalilian-Khave L, Funaro M
Expert Opin Pharmacother. 2024; 26(2):133-146.
PMID: 39708346
PMC: 11786980.
DOI: 10.1080/14656566.2024.2446623.
Serotonin Inhibition of Claustrum Projection Neurons: Ionic Mechanism, Receptor Subtypes and Consequences for Claustrum Computation.
Wong K, Graf M, Augustine G
Cells. 2024; 13(23).
PMID: 39682728
PMC: 11640313.
DOI: 10.3390/cells13231980.
Retromer Opposes Opioid-Induced Downregulation of the Mu Opioid Receptor.
Dagunts A, Adoff H, Novy B, De Maria M, Lobingier B
bioRxiv. 2024; .
PMID: 39677727
PMC: 11642924.
DOI: 10.1101/2024.12.02.626482.
Effects of psychoplastogens on blood levels of brain-derived neurotrophic factor (BDNF) in humans: a systematic review and meta-analysis.
Calder A, Hase A, Hasler G
Mol Psychiatry. 2024; 30(2):763-776.
PMID: 39613915
PMC: 11753367.
DOI: 10.1038/s41380-024-02830-z.
Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.
Sabe M, Sulstarova A, Glangetas A, De Pieri M, Mallet L, Curtis L
Mol Psychiatry. 2024; 30(3):1223-1255.
PMID: 39592825
PMC: 11835720.
DOI: 10.1038/s41380-024-02800-5.
Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics.
Chaves C, Dos Santos R, Dursun S, Tusconi M, Carta M, Brietzke E
Front Psychiatry. 2024; 15:1485337.
PMID: 39568756
PMC: 11576444.
DOI: 10.3389/fpsyt.2024.1485337.